

Frontiers in Clinical Drug Research

(Anti Infectives)



Editor:
Atta-ur-Rahman, *FRS*

Bentham Books

Frontiers in Clinical Drug Research-Anti-Infectives

(Volume 6)

Edited by

Atta-ur-Rahman, *FRS*

*Kings College, University of Cambridge,
Cambridge, UK*

Frontiers in Clinical Drug Research-Anti-Infectives

Volume # 6

Editor: Atta-ur-Rahman, *FRS*

ISSN (Online): 4674/542:

ISSN (Print): 4574/5434

ISBN (Online): ; 9: /; : 3/36/4796/7

ISBN (Print): ; 9: /; : 3/36/4795/:

©2042, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 DIRECT-ACTING ANTIVIRAL DRUGS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION-CLINICAL TRIALS DATA AND CHEMISTRY OF NS3/4A PROTEASE INHIBITORS	1
<i>Milan Sencanski cpf Sanja Glistic</i>	
INTRODUCTION	2
NS3/4A PROTEASE INHIBITORS IN DAAS COMBINATION THERAPY - APPROVED REGIMENS AND CLINICAL TRIALS	4
Paritaprevir	4
Grazoprevir	5
Glecaprevir	6
Voxilaprevir	7
NS3/4A PROTEASE STRUCTURE AND ACTIVE SITE	9
NS3/4A PROTEASE INHIBITORS – DESIGN, DISCOVERY AND CHEMICAL SYNTHESIS	14
Asunaprevir	14
Danoprevir	19
Deldeprevir	22
Glecaprevir	24
Grazoprevir	27
Narlaprevir	31
Vedoprevir	33
Voxilaprevir	35
CONCLUDING REMARKS	37
ABBREVIATIONS	38
CONSENT FOR PUBLICATION	39
CONFLICT OF INTEREST	39
ACKNOWLEDGEMENTS	39
REFERENCES	39
CHAPTER 2 PLANT LATICES AS ANTI-INFECTIVE COMPOUNDS	49
<i>Filippe Elias de Freitas Soares, Bruna Leite Sufiate, Evandro Ferreira Cardoso cpf Fabio Ribeiro Braga</i>	
INTRODUCTION	50
TRADITIONAL KNOWLEDGE	53
LATICES AND THEIR COMPOUNDS ARE PROMISORS IN COMBATING INFECTIOUS DISEASES	55
FUTURE PESPECTIVES	67
CONSENT FOR PUBLICATION	68
CONFLICT OF INTEREST	68
ACKNOWLEDGEMENTS	68
REFERENCES	68
CHAPTER 3 ANTIMICROBIAL MATERIALS AND DEVICES FOR BIOMEDICAL APPLICATIONS	78
<i>Felipe López-Saucedo, Guadalupe G. Flores-Rojas, Justine P. R. O. Varca, Gustavo H.C. Varca cpf Emilio Bucio</i>	
OVERVIEW OF ANTIMICROBIAL MATERIALS AND SURFACES	79

METHODS TO ACHIEVE ANTIMICROBIAL SURFACES	80
Physical Methods	81
<i>Impregnation</i>	82
<i>Physical Vapor Deposition</i>	82
Chemical Methods	84
<i>Chemical Vapor Deposition (CVD)</i>	84
<i>Grafting for Medical Devices</i>	85
<i>Electroplating</i>	86
Biomolecule Coatings	87
<i>Hydrogels</i>	88
<i>Covalent Immobilization</i>	89
<i>Layer-by-layer Coatings</i>	90
ANTIMICROBIAL MATERIALS	91
Traditional Antimicrobial Materials	91
Antimicrobial Polymers	93
<i>Design of Synthetic Antimicrobial Polymers</i>	94
<i>Polymers with Quaternary Ammonium Moieties</i>	96
<i>Effect of Alkyl Length Tails and Counterions</i>	98
Antibacterial Coatings	100
<i>Bioactive Molecules and the Impairment of Bacterial Biofilm Formation</i>	101
Antimicrobial Peptides	103
Nano-antimicrobial Materials	106
BIOCOMPATIBILITY, SAFETY ASSESSMENT, AND INTERNATIONAL STANDARDS	107
Biomaterials	107
Biocompatibility	108
International Standards	111
CONCLUSION	114
CONSENT FOR PUBLICATION	114
CONFLICT OF INTEREST	114
ACKNOWLEDGEMENTS	114
REFERENCES	114
CHAPTER 4 RECENT ADVANCES IN THE TREATMENT OF TOXO-PLASMOSIS	127
<i>Nagwa Mostafa El-Sayed</i>	
INTRODUCTION	128
Current Therapeutic Treatment	130
<i>Treatment of Congenital Toxoplasmosis</i>	135
<i>Treatment of Cerebral Toxoplasmosis</i>	136
<i>Treatment of Ocular Toxoplasmosis</i>	136
Challenges in Treatment of Toxoplasmosis	138
Medicinal Plants Used to Treat Toxoplasma Infection	139
<i>Thymus Vulgaris (thyme)</i>	139
<i>Zingiber Officinale (ginger)</i>	140
<i>Melia Azedarach & Azadirachta Indica</i>	140
<i>Eurycoma Longifolia</i>	141
<i>Sambucus Nigra</i>	141
<i>Juniperus Procera</i>	142
<i>Dictamnus Dasycarpus</i>	142
<i>Tinospora Crispa</i>	142
<i>Artemisia Annua</i>	142
<i>Piperaceae Plants</i>	143

<i>Commiphora Molmol (Myrrh)</i>	143
<i>Myristica Fragrans Houtt.</i>	144
<i>Echinacea Purpurea</i>	144
<i>Tectona Grandis and Vernonia Amygdalina</i>	144
<i>Sophora Flavescens, and Torilis Japonica</i>	145
<i>Curcuma Longa</i>	145
<i>Green Algae (Chlorophyceae)</i>	145
<i>Ginkgo Biloba</i>	145
<i>Astragalus Membranaceus & Scutellaria Baicalensis</i>	146
<i>Allium Sativum (Garlic)</i>	146
<i>Allium Cepa (onion)</i>	146
<i>Aloe Vera & Eucalyptus</i>	146
Role of Nano-medicine in T .Gondii Infection Treatment	148
CONCLUDING REMARKS	153
CONSENT FOR PUBLICATION	153
CONFLICT OF INTEREST	154
ACKNOWLEDGEMENTS	154
REFERENCES	154
CHAPTER 5 ANTIMICROBIAL IMMUNOGLOBULIN PROPHYLAXIS AND THERAPY ...	165
<i>Zivkovic Irena, Minic Rajna cpf Dimitrijevic Ljiljana</i>	
ANTIBODIES	166
Natural Antibodies	166
Induced Antibodies	169
Antibody Functions	171
Mediators of Antibody Functions	172
<i>The Complement System</i>	172
<i>Fc Receptors</i>	173
HISTORICAL AND PRACTICAL ASPECTS OF IMMUNOBULIN PREPARATIONS	175
Immunodeficiency	177
<i>Primary Immunodeficiency (PID)</i>	177
<i>Secondary Immunodeficiencies</i>	178
IVIG AND HYPERIMMUNE GLOBULINS IN FIGHTING INFECTIOUS DISEASES	179
Hyperimmune Globulins in Fighting Bacterial Infections	179
<i>Diphtheria</i>	179
<i>Tetanus</i>	180
<i>Other Bacterial Infections</i>	181
Hyperimmune Globulins in Fighting Viral Infections	182
<i>Rabies</i>	183
<i>Other Viral Infections</i>	184
Summary	185
MONOCLONAL ANTIBODIES IN FIGHTING INFECTIOUS DISEASES	186
IVIG IN SEPSIS	188
THERAPEUTIC ANTIBODIES IN AUTOIMMUNE DISEASES	189
Mechanisms of IVIG in Autoimmune Disorders	190
Summary	192
IVIG FOR PROPHYLAXIS	192
CONCLUSION AND FUTURE PROSPECTS	193
CONSENT FOR PUBLICATION	193
CONFLICT OF INTEREST	193
ACKNOWLEDGEMENTS	193
REFERENCES	194
SUBJECT INDEX	228

PREFACE

The 6th volume of **Frontiers in Clinical Drug Research – Anti Infectives** comprises five chapters that cover a variety of topics including prolonging antibiotic life, antimicrobial materials and devices, treatment of various infectious diseases.

In chapter 1, Sencanski and Glisic present an overview on Direct-Acting antiviral drugs for treatment of Hepatitis C Virus (HCV) that covers the latest therapeutic advances that can potentially convert chronic HCV into a routinely treatable disease. The introduction of direct-acting antivirals (DAAs) has improved efficacy and tolerance of treatments with high cure rates. A literature review was conducted to identify published clinical trial results regarding DAA combination therapy with third generation NS3/4a protease inhibitors. Detailed attention is given to the chemistry of the approved NS3/4a drugs and candidate therapeutics in advanced stages of development. In this regard, a review of key drug design and organic synthesis stages is presented for anti-NS3/4A DAAs.

In chapter 2, Soares *et al* explain how lattice plants can be used as a source of anti-infective compounds, Bucio *et al* in chapter 3 present recent developments on current antimicrobial materials as well as strategies for obtaining antimicrobial surfaces and coatings and their properties. In addition, the safety assessment of biomedical applications and international standards are also discussed in this chapter.

Chapter 4 by Mostafa El-Sayed gives an update on the current progress in the development of new drugs for the treatment of toxoplasmosis. In the last chapter of the book by Irena *et al*. the authors provide an insight into the current knowledge of the usage of antibody preparations, efficacy and mechanisms of action, with respect to specific diseases, including the treatment of infectious diseases and future prospects.

I would like to thank all the authors for their excellent contributions that will be of great interest. Also, I would like to thank the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Director Publications), Mr. Obaid Sadiq (In-charge Books Department) and Miss Asma Ahmed (Manager Publications) for their support.

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Bruna Leite Sufiate	Experimental Parasitology Laboratory, Department of Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil
Dimitrijevic Ljiljana	Department of Scientific Research, Institute of Virology, Vaccines and Sera, »Torlak«, Vojvode Stepe 458, 11000, Belgrade, Serbia
Emilio Bucio	Departamento de Química de Radiaciones y Radioquímica, Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City 04510, Mexico
Evandro Ferreira Cardoso	Experimental Parasitology Laboratory, Department of Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil
Fabio Ribeiro Braga	Department of Microbiology Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil
Felipe López-Saucedo	Departamento de Química de Radiaciones y Radioquímica, Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City 04510, Mexico
Filippe Elias de Freitas Soares	Experimental Parasitology Laboratory, Department of Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil
Guadalupe G. Flores-Rojas	Departamento de Química de Radiaciones y Radioquímica, Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City 04510, Mexico
Gustavo H.C. Varca	Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP, São Paulo, Brazil
Justine P.R.O. Varca	Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP, São Paulo, Brazil
Minic Rajna	Department of Scientific Research, Institute of Virology, Vaccines and Sera, »Torlak«, Vojvode Stepe 458, 11000, Belgrade, Serbia
Milan Sencanski	Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, Belgrade, Serbia
Nagwa Mostafa El-Sayed	Medical Parasitology Department, Research Institute of Ophthalmology, Giza, Egypt
Sanja Glisic	Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, Belgrade, Serbia
Zivkovic Irena	Department of Scientific Research, Institute of Virology, Vaccines and Sera, »Torlak«, Vojvode Stepe 458, 11000, Belgrade, Serbia

CHAPTER 1**Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus Infection-Clinical Trials Data and Chemistry of NS3/4a Protease Inhibitors****Milan Sencanski and Sanja Glisic****Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, Serbia*

Abstract: The hepatitis C virus (HCV) infection is a major and rising global health problem, affecting more than 71 million people worldwide. HCV is connected with several hepatic and extrahepatic disorders, containing several malignancies. Improved HCV detection with combined simple, well-tolerated treatments could reduce the need for liver transplantation and HCV related mortality. The latest therapeutic advances might convert chronic HCV into a routinely treatable disease. The introduction of direct-acting antivirals (DAAs) has improved efficacy and tolerance of treatments with high cure rates. DAAs target specific nonstructural proteins of the HCV with consequential interference with viral replication and consequently infection. The majority of the FDA approved drugs for HCV and those pending approval are small molecule drugs, especially those that utilize the viral inhibitor mechanisms of action and favor the HCV nonstructural proteins as their targets. Therefore, DAAs represent the most promising anti-HCV drugs that carry the least risk of drug failure during clinical trials. NS3/4a protease inhibitors have become the basis for HCV treatment as most new therapies contain an inhibitor from this class. It is reported that the approach for combating chronic viral infections is best achieved by a combination of several strategies, by means of inhibiting several targets. Moreover, the best promising strategy for fighting HCV is most similar to the anti-HIV therapy. A literature review was conducted to identify published clinical trial results regarding DAA combination therapy with third generation NS3/4a protease inhibitors. Detailed attention is given to the chemistry of the approved NS3/4a drugs and candidate therapeutics in the advanced stages of development. In this regard, a review of key drug design and organic synthesis stages is presented for anti-NS3/4A DAAs.

Keywords: Chemical Synthesis, Clinical Trials Data, Drug Design, Direct-Acting Antivirals, Hepatitis C Virus, NS3/4A protease, Protease Inhibitors.

* **Corresponding author Sanja Glisic:** Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, Serbia, E-mail: sanja@vinca.rs

INTRODUCTION

Chronic HCV infection with an approximate worldwide prevalence of 1% is a worldwide health problem, affecting 71 million people with 1.75 million persons newly infected each year [1, 2]. HCV has been reported as the principal cause of chronic liver disease, cirrhosis, and liver cancer [3].

A sustained virological response (SVR) to antiviral therapy remarkably alters the course of liver disease related to the HCV infection by lowering the frequency of hepatic decompensation, liver cancer, liver-related mortality, all-cause mortality, and liver transplantation [4, 5]. The previous standard-of-care treatment for chronic HCV, before 2011, was a PEGylated interferon (PEG-IFN) and ribavirin (RBV) combination (PEG-IFN/RBV), a dual therapy that has been used for more than 15 years [6]. This long and costly therapy was associated with serious adverse effects [6, 7]. The introduction of therapy with direct-acting antivirals (DAAs), anti-HCV drugs that directly target HCV proteins, is considered as a key advancement in HCV therapy offering higher cure rates and the least adverse events. NS3/4A protease inhibitors - telaprevir and boceprevir in 2011 became the first FDA-approved DAA drugs. With the treatment with one of the first generation NS3/4A protease inhibitors in combination with PEG-IFN more than 75% patients infected with the HCV genotype 1 achieved an SVR, but this therapy was associated with serious side effects, increased daily pill burden and drug resistance [8, 9]. As a result of drawbacks of the first-generation HCV protease inhibitors better therapeutics of the second-generation were developed. Reduced demand for the first generation drugs due to the availability of newer HCV drugs with higher efficacy and fewer side effects, along with the fact that they were no longer recommended by the WHO, has stopped their production [10]. In an astonishing revolution in the treatment of chronic HCV the second phase commenced in 2015 with a regimen of DAAs in combination with 2 or 3 second-generation DAAs that target HCV viral proteins (NS3/4A protease inhibitors, NS5B nucleos(t)idic and non-nucleos(t)idic polymerase inhibitors, NS5A replication complex inhibitors) without IFN and RBV for 8 to 16 weeks based on baseline factors such as the stage of fibrosis, viral genotype and subtype, baseline viral load, former treatment history (naive or experienced) and resistance-associated variants. The majority of the new HCV treatment combinations have an immense antiviral impact (virological cure or a SVR > 95%), fair tolerance and a lower pill burden [11]. The third phase in the HCV treatment revolution has recently emerged with the introduction of the pangenotypic DAAs, suitable for all HCV genotypes. Current, up-to-date, oral antiviral DAA combination therapy shows supreme treatment efficacy, safety and tolerability. The third-generation pangenotypic NS3/4A protease inhibitors (mainly glecaprevir (GLE) and voxilaprevir (VOX)) possess both high antiviral

activity and a genetic resistance barrier with cure rates of over 95% regardless of the presence of baseline resistance associated variants [12]. In addition these regimens are well tolerated with low incidence of side effects, even in the difficult-to-treat population (*e.g.* compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment) [12, 13]. Similarly, in another difficult-to-treat subgroup of HCV patients with genotype 3, which constitutes 30% of the global HCV population, pangenotypic protease inhibitor, glecaprevir–GLE coformulated with pibrentasvir, an NS5A inhibitor, show potential with high SVR rates [14].

Despite improved HCV detection, still fewer than 20% of people living with HCV are aware of their infection, so attention should be directed to engage, screen, and diagnose everyone in need of therapy while improving access to quick, simple, and affordable HCV diagnostics at the point of care. The above mentioned issues are crucial to attain global HCV elimination [15, 16]. According to current international guidelines genotype testing is still recommended before HCV treatment commencement [17, 18], although the new pangenotypic DAA regimens no longer depend on quantitative HCV RNA or genotype data to stratify the duration of treatment. Also many current international clinical trials collect evidence of the efficacy of simplified approaches for diagnosis and treatment monitoring [16, 19]. Current new DAA combinations with a pangenotypic third generation NS3/4A protease inhibitor represent an opportunity in low and middle-income countries with limited resources to treat HCV infected patients without prior costly genotype testing. These issues regarding diagnostic simplification and cost-reduction are crucial for carrying out HCV screening and treatment in resource limited countries [20].

HCV NS3/4a protease inhibitors inhibit the enzymatic activity of NS3/4A and have a crucial role in the development of contemporary therapies for HCV. Of note is that this class of drugs has become a mainstay of HCV treatment as most new therapies contain an inhibitor from this class. HCV is a positive-stranded RNA virus whose genome encodes a polyprotein processed into at least 10 viral structural and nonstructural (NS) proteins: C, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B [21]. HCV NS proteins, originating from the proteolytic degradation of the polyprotein are part of the cellular replication complex which is essential for viral replication. The NS3 protein has an N-terminal serine protease domain and a C-terminal RNA-dependent ATPase domain. NS4A represents a co-factor for the activity of NS3 serine protease [21]. Since HCV NS3-4A protease is essential for viral replication it represents an attractive target for developing new anti-HCV therapies.

Surrogate endpoints are often used in clinical trials, as they allow for indirect

Plant Latices As Anti-Infective Compounds

Filippe Elias de Freitas Soares^{1,*}, Bruna Leite Sufiate¹, Evandro Ferreira Cardoso¹ and Fabio Ribeiro Braga²

¹ *Experimental Parasitology Laboratory, Department of Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil*

² *Department of Microbiology Veterinary Medicine - University of Vila Velha, Espírito Santo, Brazil*

Abstract: Infectious diseases are caused by pathogenic microorganisms, such as bacteria viruses, or fungi, and can be spread, directly or indirectly, from one person to another. Among these diseases, AIDS, tuberculosis, influenza, hepatitis and neglected tropical diseases, such as dengue and malaria, stand out. On the other hand, emerging infectious diseases are infections that have recently appeared in a population or those whose incidence or geographical range is rapidly increasing and/or threatens to increase in the near future. Since the 1970's, approximately 40 infectious diseases have been discovered, including SARS, MERS, Ebola, Chikungunya, avian and swine flu, and, most recently, Zika. The transmission modes for the different existing infectious diseases vary greatly, among them the most common are through water and food, vectors, zoonosis (diseases transmitted by animals), sexual transmission, blood, air and soil. Anti-infective drugs development and the remarkable eradication of smallpox in the 1980's, following a global immunization campaign led by the WHO (World Health Organization), generated the hope that infectious diseases could be controlled and even eliminated. However, the current perception that infectious diseases continue to emerge and re-emerge (including the possibility of bioterrorism), highlights the future challenges in infectious diseases research. The modern medicine needs new anti-infective drugs in order to treat specific drug-resistant infections at the same time as the drug development pipeline is almost dry. Thus, the development of new drugs and anti-infective compounds is needed, such as the use of plant-derived latex, which is well studied and present great potential. Therefore, the objective of the present chapter is to give an overview regarding the use of plant-derived latices as anti-infective compounds, as well as to point out new perspectives on this matter.

Keywords: Anti-infective, Enzymes, Plant latex, Secondary metabolites, Traditional knowledge

* **Corresponding author** **Filippe Elias de Freitas Soares:** Department of Chemistry, Federal University of Lavras, Lavras, Minas Gerais, CEP 37200-900, Brazil; Fax: +55 (31) 3899-3048; E-mail: filippeufv@yahoo.com.br

Atta-ur-Rahman (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

INTRODUCTION

Nature has been a source of medicinal products for millennia, with many useful drugs developed from plant sources [1]. In addition, medicinal plants and fruits have been used by indigenous peoples for centuries as sources of extracts used in the treatment of a variety of problems. Among the parts of plants used, latex has broader ethno-pharmacological applications as it is used by local tribal communities for wound healing, burns, joint pain, and for controlling worm infections. Moreover, plant latex is used in industry to make all sort of products, *e.g.* paintings, elastics, swim caps, condoms, catheters, medical gloves, balloons and chewing gum. It is also mixed in cement as an additive, providing quick physical strength for solidification [2].

About 20,000 species from 40 families are estimated to have laticifers, although so far only 12,500 plant species of 22 families have been identified [3]. Latex is found in dicotyledonous and monocotyledonous plants and, actually, nearly 10% of families and species produce latex [4], which are found in unrelated plant orders, suggesting polyphyletic origins [5].

On the other hand, latex is more frequently observed in tropical plants, with high prevalence percentages of laticiferous families and species (respectively, 12.2% for families and 14.0% for species) [6]. Some notorious laticiferous plants are: *Hevea brasiliensis*, *Carica papaya* and *Ficus* spp.

Latex is an aqueous suspension or emulsion, derived from living cells. It is a complex mixture of peptides, enzymes, triterpenoids, diterpenoids, amino acids, alkaloids, starches, sugars, oil, tannins, and other compounds [7]. In most plants, latex is white, but some have yellow, orange, or scarlet latex [4]. Moreover, latex tends to be more phytochemically diverse than resins, mucilages and gums [8]. Resin is distinct from latex because it is kept in canalicular inter-cellular spaces called resin ducts and is not kept inside cells [9]. Resin is a plant exudate common in conifers and some angiosperms (*e.g.*, Anacardiaceae), rich in terpenoids and phenolics, and stored in intercellular spaces. Mucilage is another plant exudate, composed of sticky polysaccharides that is often clear and exude from the phloem. Gum is distinct from the above mentioned plant exudates once it is composed of water-soluble polysaccharides that are exude from cellular cavities or bark [10]. On the other hand, latex is produced and then stored, rarely, in parenchyma cells or more frequently in the tube structures known as laticifers [11].

Laticifers are tissues composed of extremely elongated cells that extend throughout the plant that exude the latex, whose main origin is from vacuoles. In general, these cells are distributed in various tissues of the plant body, *e.g.* roots,

stems, petioles and leaves [9]. Based on their development and structural characteristics, laticifers can be classified as: articulated and nonarticulated laticifers [11 - 13].

Nonarticulating laticifers are formed from single cells that often branch, but do not loop or reconnect. Since the laticifers branch, but never merge, the formed laticifers have tree-like shapes without loop structures. The cells undergo karyokinesis without cytokinesis, resulting in coenocytic cells [14 - 16]. On the other hand, articulated laticifers have a compound origin as they develop from multiple cells. Articulating laticifers form loops and are often connected by perforations in the cell walls of neighboring laticifers [10, 14, 15].

Thus, if a plant with laticifers are injured, latex will be immediately secreted. Not unlike the blood of animals, when it occurs, latex oozes out, becomes sticky when exposed to air, and quickly coagulates. The coagulation process is vital for plant defence against possible pathogens attack [4, 10]. Unlignified organs (soft) are food for insects, while lignified organs (hard) are attacked by microbes at wound sites, so the diversity in latex structure and composition is most likely an organ-specific adaptation to different potential pests [17].

Plants are continuously challenged by bacteria, fungi, oomycetes, nematodes, insects and other pathogens and herbivores. Various secondary metabolites and proteins provide resistance to herbivores *via* toxicity, antinutritive and “mire” effects. In general, specialized latex metabolites are biochemical end products that do not reenter primary metabolism. There is no strict association between compound class and laticifer type [2, 5, 10, 18]. Latex metabolites vary between species and families of plants, for example, we can find terpenoids in *Hevea brasiliensis*, cardiac glycosides in the Apocynales, alkaloids (morphine, codeine, and papaverine) in *Papaver somniferum*, phenolic glucosides in *Cannabis sativa*, sugar in Asteraceae and tannins in Musa, Aroideae [16]. Konno [9] reviewed in details the chemicals (mostly secondary metabolites but some primary metabolites) and proteins from plant latex and other exudates (Fig. 1).

Latex protein constituents vary among organs in a single species, for example, as shown for young petioles and immature fruit of *Ficus carica* [17]. Different classes of enzymes and proteins have been found from plant latex, for example: papain-like cysteine proteases (PLCPs), chitinases, lectins, protease inhibitors and oxidases [9]. Let's take a good look at these proteins.

According to the Commission on Enzymes of the International Union of Biochemistry, proteases or peptidases, enzymes that catalyze the hydrolysis of the peptide bond between amino acid residues of a protein, are classified as EC 3.4. Therefore, proteases belong to group 3 (hydrolases), and subgroup 4 (which

Antimicrobial Materials and Devices for Biomedical Applications

Felipe López-Saucedo¹, Guadalupe G. Flores-Rojas^{1,*}, Justine P. R. O. Varca², Gustavo H.C. Varca² and Emilio Bucio^{1,*}

¹ Departamento de Química de Radiaciones y Radioquímica, Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City 04510, Mexico

² Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP, São Paulo, Brazil

Abstract: Bioaccumulation in sanitary devices, caused by opportunistic pathogens, intervenes negatively in the recovery of a patient since these are able to provoke a mild or life-threatening infection. Thus, surfaces of certain materials such as gauzes, catheters, sutures, *etc.*, which are adjacent or directly exposed to a healing zone, are prone to become sites for the growth, proliferation, and spread of pathogenic microorganisms. Although in surgical or healing processes, sterile materials are usually applied, the time of contact with biological interfaces is long enough to make the sterilization but not enough to control and prevent an infection since pathogens abound in the surroundings. Air, water, and soil can be potential vectors, without considering those factors related to iatrogenesis that also play a role in the opportunities for the patient's recovery. Within this context, engineered materials are currently being developed and explored towards devices and biomaterials with improved design, performance, duration, biocompatibility aiming to be safer for the user. The surface functionalization of materials with antimicrobial agents is a highlighted alternative to overcome this issue. This chapter addresses current antimicrobial materials, as well as strategies for obtaining antimicrobial surfaces and coating as well as their properties. In addition, the safety assessment of biomedical applications and international standards are discussed.

Keywords: Antimicrobial agents, Antimicrobial surfaces, Advanced materials, Biomedical devices, Biological evaluation, Bioactive molecules, Coatings, International standards, Safety assessment, Surface functionalization.

* Corresponding authors Guadalupe G. Flores-Rojas and Emilio Bucio: Departamento de Química de Radiaciones y Radioquímica, Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City 04510, Mexico; E-mails: ggabofo@hotmail.com; ebucio@nucleares.unam.mx

Atta-ur-Rahman (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

OVERVIEW OF ANTIMICROBIAL MATERIALS AND SURFACES

Since ancient times, the history of humanity reveals a constant struggle to fight bacteria and other pathogenic microorganisms. Infections are responsible for a vast number of deaths around the world, and before the outbreak of antibiotics discovery, for instance, several materials with anti-microbial properties were applied. Therefore, an adequate anti-infective strategy is crucial in hospitals and demands great efforts against the outbreaks of infections, which are triggered by a wide variety of microorganisms.

Some of the most common pathogens infections are caused by *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Candida albicans*, *Candida aspergillus*, etc., which are responsible for several illnesses that tend to be developed from mild to life-threatening if undesirable proliferation takes place in the human body. These include skin and wound infections, eczema, abscesses, endocarditis (biocontamination of heart valves), pneumonia, onychomycosis, candidiasis or thrush (both vaginal and oral), aspergillosis, etc.

Nevertheless, the pathogens are not restricted to the colonization of surfaces but also they invade interstitial extracellular cavities, and are capable of internalizing in the cells of the connective tissue [1, 2]. Thus, the pathogens can survive to chemotherapy treatments, because these are well protected by the intracellular reservoir, ready to start the infection again, once antimicrobial concentrations have lost their efficacy.

Consequently, the use of antibiotics able to reach intracellularly hidden bacteria is crucial. One of the challenges is that the antibiotics penetrate the membranes of eukaryotic cells, since antibiotics as gentamicin are incapable of reaching the intracellular compartment, and even the gentamicin-laden biomaterials, occasionally turn into ineffective or even a counterproductive option in cases where strains capable of cell internalization are involved in the infection, such as *S. aureus*, which is a typical pathogen [3].

In principle, the use of microbial agents would be a perfect fit if bacterial resistance, among other problems, would not arise from the use, misuse or overuse of antimicrobial agents. Within this context, technological advancements have been directed to control pathogenic growth or population on surfaces, for example, as fighting infections locally seems a lot more effective and rationale than fighting it at a systemic level, as it would require fewer amounts of antibacterial agents and control the infection on site.

The concept of controlling and designing antibacterial surfaces has a direct and deep impact on reducing healthcare-associated infections and mortality. Overall,

this promising technology holds a relevant contribution economically, industrially and from a healthcare perspective. In addition, such materials, also named self-cleaning devices, compose a more sustainable system as depending on the technology applied, none or almost no antimicrobials are released to the ecosystem, thus also being entitled as environmentally friendly.

The topic is, focused on the ability to control the pathogenic population in distinct environments, specially, bound to catheter materials or devices, when in direct or indirect contact with the body over time. At first glance, sterilization of medical devices assures acceptable levels of decontamination concerning biomedical applicators. However, it is limited and variably effective in controlling the pathogenic microorganisms that will persist grow, and induce biofilm formation on the material or devices over time.

In such conditions, strategies to control bioburden abound and not limited to selective killing towards a specific pathogen, or using antimicrobial or static agents is paramount. This measure in addition, is driven towards controlling or modifying surfaces to block or modulate bacterial adhesion or growth.

METHODS TO ACHIEVE ANTIMICROBIAL SURFACES

One way to classify antimicrobial materials is based on physical, chemical, and biological synthesis methods. In this section, the chemical methods are referred to those, which are compounds involved in the interaction *via* covalent bonds, to immobilize or functionalize materials, regardless of the origin of the antimicrobial agent. On the other hand, the physical methods are limited to surface coating or blending where there is no chemical transformation of the matrix or biomedical devices and both retain their whole functional identity. The third approach comprises the modifications or functionalization with antimicrobial biomolecules. This type of coating and/or immobilization is frequently studied separately as the antimicrobial properties are featured by the biomolecule or its derivative that provides effectiveness. These methods usually are less harsh as they require milder reaction conditions, medium, pH, or temperature.

In fact, some materials require the use of a combination of these methods to provide effective antimicrobial measures. The main criterion in choosing an adequate method and type is in accordance with the nature of the matrix and the reactants. Indeed, most of the current antimicrobial materials involve both chemical and physical types of modifications, these can be considered mixed methods [4].

Despite the significant number of methods listed in literature for obtaining

CHAPTER 4

Recent Advances in the Treatment of Toxoplasmosis

Nagwa Mostafa El-Sayed*

Medical Parasitology Department, Research Institute of Ophthalmology, Giza, Egypt

Abstract: Toxoplasmosis is caused by an obligate intracellular parasite, *Toxoplasma gondii* (*T. gondii*) which infects about thirty percent of the world human population. Infection occurs by the consumption of *Toxoplasma* tissue cysts in raw or undercooked infected meat, intake of the contaminated food or water with *Toxoplasma* oocysts shed in the feces of an infected cat, blood transfusion, placental transmission or organ transplantation. Toxoplasmosis is the most common opportunistic infection in the pregnant women and the immunocompromised individuals resulting in severe complications as encephalitis, pneumonitis and myocarditis with high mortalities. Unfortunately, few effective drug therapies for this disease are available, their aim being the decrease of the parasite replication rate to prevent more pathological changes in organs involved as well as to avoid the serious complications. The recommended therapy for treatment or prophylaxis of toxoplasmosis is the combination of pyrimethamine and sulfadiazine, in spite of this combination is so effective against acute toxoplasmosis but being unsuccessful in the treatment of toxoplasmic chorioretinitis, encephalitis, and congenital toxoplasmosis. Anti-Toxoplasmic drugs need to be effective against the all stages and strains of *Toxoplasma* parasite with a higher penetration into the cerebral, ocular and placental tissues and have no side effects as fetal toxicity and teratogenic effects. Up till now, there is no available drug has all these advantages. The occurrence of side effects, the development of resistant strains and the lack of effectiveness against *Toxoplasma* tissue cyst are the main disadvantages of the current drug therapies. The discovery of drug therapies with a lower toxicity and able to prevent and treat toxoplasmosis would represent a novel era in the treatment of this infectious disease, especially in immunosuppressed patients. Therefore, the researches technology with regard to the parasite's proteomics and functional genomics are needed for the development of new and safer drug agents. Currently, an increase orientation of the pharmacological action of natural agents and medicinal plants are usually considered to be safer than synthetic drugs. The value of these plants as sources of natural product bioactive molecules to medicine related to their chemotherapeutic effect and considered as template molecules for the manufacture of new drug agents. Recently, most of the researches in the drug development for toxoplasmosis focus on the use of nanotechnology for improving the

* **Corresponding author Nagwa Mostafa El-Sayed:** Medical Parasitology Department, Research Institute of Ophthalmology, 2El-Ahram St, Intersection of El Bahr El Aazam St, Giza 12556, Egypt; E-mails: nagelsaka@hotmail.com, nag.elsaka@yahoo.com

pharmacokinetic profile of drugs. The combination of nanoparticles and plant extracts to give rise broad spectrum of drugs may be a greater chance for defeating *Toxoplasma* infection. This chapter aimed at giving an update on the current progress in the development of new drugs for the treatment of toxoplasmosis.

Keywords: Current therapeutics, Medicinal plants, Nanotechnology, *Toxoplasma gondii*, Treatment.

INTRODUCTION

Toxoplasmosis is an infectious disease caused by the intracellular parasite, *Toxoplasma gondii*. Humans acquire the infection by consumption of undercooked or raw meat from infected animals or consumption of food or water contaminated with oocysts excreted infected cats. Other different routes of transmission include transplacental, organ transplantation and blood transfusion. The laboratory workers who handle cultures and animal models with this parasite and also butchers and slaughterhouse workers are in danger [1 - 3].

Toxoplasmosis affects about 30% of the world's population. This wide geographic distribution is expounded to many factors, as food habits contact with infected cat excreta and variations in climate. In immunocompetent individuals, *T. gondii* infection is mostly asymptomatic or may produce flu-like symptoms, and sometimes associated with lymphadenopathy. It is usually followed by a lifelong latent infection [4]. Toxoplasmosis occurred in a fetus and immunocompromised hosts might lead to a severe illness or maybe fatal damage [5]. The outcome of the infection by *Toxoplasma* depends on the interaction of the many factors, including the status of the host immune system and parasite factors, like parasite inoculum, infective stage, and genotype of isolate.

T. gondii organism has different stages: tachyzoites (active stage), tissue cyst stage containing bradyzoites (dormant stage), and sporozoites (in oocysts). The biology of these stages is considered a vital area in research that will be important for the discovery of anti-toxoplasmic agents. In the acute phase of toxoplasmosis, metabolically active tachyzoites destroy tissues and disseminate throughout the body, resulting in clinical manifestations and most drugs used to treat toxoplasmosis significantly affect the tachyzoites. When the chronic infection establish, the tachyzoites turn into dormant tissue cysts (the resistant form) that persist with the host's life. If the host's immunity suppressed, the tissue cysts might rupture, and the bradyzoites will turn back to active tachyzoites, resulting in severe complications [6]. Most anti-*Toxoplasma* agents do not have an effect on the tissue cysts as they encircled by a resistant cyst wall. Moreover, *Toxoplasma* tissue cysts generated within the brain are protected by the blood-brain barrier that results in difficulty in the treatment [7].

During the infection process, *Toxoplasma* bradyzoites or sporozoites invade the intestinal epithelium and spread to the mesenteric lymph nodes and then enter the bloodstream, and come across the biological sites as the blood-brain-barrier, the blood-retina barrier and also the placenta [8]. *Toxoplasma* invades various organs and infects a wide variety of cells [9]. The primary step of the cell penetration by *T. gondii* is that the recognition of an attachment point by its special organelles, rhoptries and micronemes, each discharging proteins throughout the invasion methods [10]. After the cellular invasion, the organism allays in a vacuole, derived from the host cell's plasma membrane [11] and asexually multiplies causing cellular disruption and death. Leading necrosis attracts inflammatory host cells, as lymphocytes and monocytes. This response causes the major pathology in infected individuals. As host resistance develops, usually around 3 weeks post-infection, tissue cysts may form in several organs, primarily within the brain and muscles. These dormant cysts enable *T. gondii* to evade the adaptive host immunity. As tissue cysts periodically rupture, the free bradyzoites are killed by the immune system of the host. If the immune system becomes compromised due to chemotherapy or AIDS, these bradyzoites transform to tachyzoites, causing active infection [9]. Immunocompromised patients need therapy to control progressive disease, and the therapy should be continued for the period of cell-mediated immunological disorder to prevent recrudescence [12].

Toxoplasma gondii has 3 main genotypes which differ in the virulence and epidemiological manner. Type I strain is a high virulence for mice [13] and has been recorded in the patients with ocular [14] and congenital toxoplasmosis and additionally was related to offspring cerebral toxoplasmosis [15]. Type II is non-virulent for mice but causes latent infection with the formation of tissue cysts. This strain is also most commonly related to human infections in Europe and North America [13]. Type II strain has been registered in patients with congenital disease and AIDS patients [16, 17]. Type III is non-virulent for mice and less occurring than type II in Europe and North America. This Type is the most recurrent strain in the animals [13].

Toxoplasma gondii is able to infect the most internal organs and tissues of the mammalian host. In the host cells, *T. gondii* generates DNA damage and causes rapid cell death with rupture and liberation of the free organisms and soluble antigens that lead to several histopathological changes in the influenced organs and tissues ranging from mild congestion to severe degeneration [18, 19].

Because of the medical importance of toxoplasmosis, it's necessary to study the prevalence of this parasitic infection among different human populations from the different areas of the world. Epidemiological studies help in evaluating the morbidity level and the burden of human toxoplasmosis and should be useful for

Antimicrobial Immunoglobulin Prophylaxis and Therapy

Zivkovic Irena*, Minic Rajna and Dimitrijevic Ljiljana

Department of Scientific Research, Institute of Virology, Vaccines and Sera, »Torlak«, Vojvode Stepe 458, 11000, Belgrade, Serbia

Abstract: Immunoglobulins, either natural or induced, represent powerful means for eliminating microbial threats. For decades, vaccines have been used which function by inducing antibodies for the successful elimination of microbes, preventing disease and mortality.

Polyclonal immunoglobulin products from human plasma were used for the first time to treat immune deficiency during the 1950s. Nowadays, the administration of immunoglobulin, either intravenous or subcutaneous, is the cornerstone of the treatment of primary immunodeficiency affecting the humoral immune system. The therapy can help people with weakened or underdeveloped immune system fight off infections. This is also the treatment of choice for certain autoimmune and neurological diseases.

The polyclonal antibody preparation consists of both natural antibodies and antigen-induced antibodies and reflects the history of antigen experience of the donor population. Natural antibodies are germline-encoded, polyspecific, low-affinity antibodies that also have a regulatory role in maintaining the immune system homeostasis. Antibody preparations, enriched for certain desired specificities, or hyperimmune human globulins are used for prophylaxis and treatment of infectious diseases with a high mortality rate.

It was shown that lymphocytes from survivors of viral infections, without available vaccines, could be used for protective monoclonal antibodies production. This chapter provides insight into the current knowledge of the usage of antibody preparations, efficacy and mechanism of action, with respect to specific diseases, including the treatment of infectious diseases and future prospects.

Keywords: High mortality rate infectious diseases therapy, IVIG, Inflammation, Immunodeficiency, Induced antibodies, Monoclonal antibodies, Natural antibodies, Passive immunotherapy, SCIG, Sepsis.

* **Corresponding author Zivkovic Irena:** Department of Scientific Research, Institute of Virology, Vaccines and Sera, »Torlak«, Vojvode Stepe 458, 11000, Belgrade, Serbia; Tel: +381 11 3953 700; Fax: +381 11 2468 883; E-mail: izivkovic@torlak.rs

ANTIBODIES

Antibodies are one of the components of humoral immunity excreted by specialised cells -- B lymphocytes, also known as plasma cells. In terms of localisation, antibodies can be membranous, present at the surface of B cells, or soluble, present in the serum, or secretions. Membrane-attached antibodies are part of the B cell receptor complex, which when activated induces the release of antibodies in the soluble form. Several grams of antibodies per litre of plasma circulate throughout the body *via* the bloodstream. These antibodies have multiple specificities and can reach remote locations in the periphery within minutes. Antibodies are involved in a variety of biological responses in both health and disease. They can have both protective and pathological roles. Immunization-induced specific antibodies account for the therapeutic effects of the overwhelming majority of vaccines, whether prophylactic or therapeutic.

Each antibody molecule is composed of two structural units: the variable antigen binding domain, which is dual in each molecule and is designated Fab, and a constant region which is constant within an antibody class/subclass, termed the Fc region. Antibodies bind antigens through the Fab regions with a wide range of affinities and the majority of biological activities of antibodies are mediated by the Fc region which interacts with a wide range of molecules (receptors) leading to different effector functions.

Based on the kind of heavy chain Fc region, there are 5 different antibody classes or isotypes (IgD, IgM, IgA, IgG and IgE). Additionally, some antibody classes comprise structurally different groups of molecules and hence in humans, there are four IgG subclasses (IgG1, IgG2, IgG3 and IgG4), which were numbered according to their abundance in the serum such that IgG1 is the most abundant. Each antibody class/subclass has a specific role in the immune response; in directing the immune response based on the type of antigen that provoked the response. IgA is the main antibody in mucosal defence, IgE in defence against parasitic worms, whereas antibody-mediated response against other pathogens comprises highly specific IgG. In terms of abundance in the serum, antibody classes follow IgG>IgA>IgM>IgD>IgE.

Based on the mode of induction, antibodies can be divided into natural antibodies or infection/immunisation-induced antibodies.

Natural Antibodies

In the sera of healthy humans and animals, antibody molecules exist which are not induced by a foreign antigen, and which are called Natural antibodies (NAb). Apart from serum, NABs can be found in other bodily fluids such as the

colostrum, saliva and cerebrospinal fluid [1 - 4]. NAb can be of the IgM, IgA and IgG class [5]. NAb in the newborn mostly belong to IgM antibody class (80%), whereas in adults IgG class predominates [6]. NAbs are not initially induced in a specific immune response [7]. In mice, NAbs are secreted by specialised B cells. Immediately after birth, the main and probably the only source of natural IgM antibodies is a small population of B lymphocytes designated as B1 cells [8]. B1 cells in mice differ from conventional B cells in terms of origin, activation requirements, and signal transduction pathway upon the engagement of the B cell receptor. The characteristic of these B1 cells is the CD5 surface antigen expression (which is also expressed on T cells) which, upon activation, suppresses the BCR-induced proliferation signal. The differentiation of B1 cells takes place during fetal development, after which these cells are mainly located in the pleural and peritoneal cavity throughout life. B1 cells are long-lived with the capacity to self renew.

The major characteristics of NAbs are that they are polyreactive, specific for either endogenous structures, part of self, or for foreign antigens [4]. Research on the topic revealed that NAbs actually mostly recognize self-antigens, therefore a more accurate description would be that NAbs repertoire is mostly composed of autoantibodies which have the capacity to bind pathogens as well. During maturation, NAb producing B1 cells go through a positive selection towards self antigens, without the development of autoimmunity, which is probably due to the low affinity of these antibodies.

The level of circulatory NAbs is stable during a lifetime, while the repertoire and reactivity profile of these antibodies is exceptionally stable within a species and even between species. The stability is caused by genetics. Namely, the genes for variable (V) regions of NAbs, for both the heavy (V_H) and light (V_L) chains., are generally not subjected to somatic hypermutation and display much reduced, or non-existent, N-region additions and therefore the offspring actually receives a conserved defence antibody pool. Antigen receptor diversity is increased during VDJ recombination when the enzyme terminal deoxynucleotidyl transferase is present, which adds N-additions to the V-D and D-J junctions. Such germline characteristics have been shown to be essential in NAbs' ability to protect against infection [9].

Although interesting from a mechanistic point of view, the vast differences between mice and humans are evident in the elusiveness of a well defined human B1 cell populations. It appears as if these B1 cells in humans could belong to the innate-like lymphoid cells.

A model has been proposed by Kruetzmann *et al.* [10] in which, in humans, IgM

SUBJECT INDEX

A

- Acid 13, 17, 26, 29, 32, 82, 86, 88, 90, 91, 94,
131, 135, 136, 138, 145, 152, 179
- acetic 82
 - acrylic 86, 91
 - antagonize para-aminobenzoic 131
 - artemisinin 145
 - boronic 13
 - carboxylic 26, 29, 32
 - citric 90
 - decanedionic 88
 - folinic 135, 136, 138
 - lactic 82
 - polylactic 152
 - residual caprylic 179
 - vinylcyclopropane amino 17
- Action 93, 127, 131, 141, 191
- anti-toxoplasmic 141
 - biocidal 93
 - pharmacological 127
 - protective 191
 - studied anti-Toxoplasma 141
 - synergistic 131
- Activation 9, 52, 67, 85, 167, 173, 174, 189
- immune 189
 - influence cells 174
 - polyclonal 189
 - polyclonal B-cell 189
 - premature 52
- Activity 3, 9, 24, 27, 52, 53, 55, 56, 64, 65,
66, 68, 81, 82, 90, 92, 93, 99, 103, 104,
106, 107, 130, 131, 133, 134, 135, 141,
142, 143, 144, 152, 166, 173, 190, 191
- anthelmintic 56, 64
 - antiadhesive 81
 - antibacterial 56, 99, 107
 - anti-infective 56, 68, 92
 - anti-inflammatory 64
 - antimalarial 143
 - antiparasitic 130, 141, 142
 - antiproliferative 141
 - anti-toxoplasmic 142, 144
 - anti-toxoplasmic inhibitory 144
 - antiviral pan-genotypic 24
 - bactericidal 93
 - biological 9, 65, 66, 152, 166, 173
 - broad-spectrum 93
 - enzymatic 3, 9, 82, 90
 - enzyme 27
 - immunomodulatory 52, 144
 - synergistic 103, 131
- Aggregation 98, 99
- macromolecular 98
- Aided peptide coupling 29, 36
- Alcohol 28, 34, 35, 97, 148
- ethylic 148
 - racemic 28
- Aldrich syndrome 190
- Alkaline hydrolysis 29, 32
- Alkene metathesis 24
- Alkylation 18, 99
- carbanion 18
- Ameliorating stress 143
- Amine 20, 21, 33
- aliphatic 20
 - cyclopropyl sulfonic acid 21
- Amino acid residues 9, 10, 51, 52
- marked catalytic site 10
- Ammonium compounds 97, 100, 107
- biocompatible quaternary 97
 - quaternary 100, 107
- Antibiotic delivery systems 92
- Antibiotic resistance 92, 193
- fuelling 193
- Antibiotics 79, 92, 93, 95, 103, 106, 131, 133,
134, 181, 182, 187, 193
- broad-spectrum 93
 - consumption 193
 - loaded 93
 - penetrate 79
 - semisynthetic lincosamide 131
- Antibodies 165, 166, 167, 168, 169, 171, 173,
176, 177, 181, 182, 184, 185, 186, 187,
188, 189, 190, 191, 193
- antigen-induced 165
 - anti-SARS 184

anti toxin 182
 autoreactive 169
 detected SARS 184
 neutralising 184
 pathological autoimmune 190
 pathological anti-ganglioside 191
 physiological conditions 191
 single monoclonal 186
 therapeutic 187, 189
 Antimicrobial 80, 86, 87, 88, 89, 93, 94, 95,
 99, 103, 193
 biomolecules 80
 enzymes 93
 hydrogels 88, 89
 immobilization 86
 immunoglobulin therapy 193
 metallic 87
 moieties 99
 peptides 88, 103
 polymeric systems 95
 polymers 93, 94, 95
 Antioxidant 54, 64, 139, 140, 141, 143, 147
 activity 141
 efficacy 147
 Anti-toxoplasma 128, 131, 134, 139, 140, 151,
 152
 activity 139, 151
 agents 128
 effect 139, 140, 152
 medications 131, 134
 Anti-toxoplasmosis 150
 Apoptosis signalling 174
 Aspergillosis 79
Aspergillus 58, 63, 66
 flavus 58
 niger 58, 63, 66
 Atom transfer radical polymerization (ATRP)
 89
 Autoantibodies 167, 169, 173, 190
 circulating IgG 169
 endogenous pathological 190
 pathogenic 169
 purified natural serum IgG 169
 Autoimmune 169, 173, 178, 189, 190, 192
 diseases 169, 189, 190
 disorders 190
 hemolytic anemia 173
 lymphoproliferative syndrome 178
 myositis 192
 nature 189

Autoimmunity 167, 168, 169, 189, 190, 192
 development of 167, 189
 disorders 189
 induction 189
 physiological 169
 Autoinhibitory prodomain 52

B

Bacteria 97, 168
 encapsulated 168
 planktonic 97
 Bacterial adhesion 80, 100, 101
 reducing 101
 Bacterial 101, 105
 AMP resistance mechanisms 105
 biofilm formation 101
 Bacterial infections 106, 178, 179, 181, 192,
 193
 repeated 178
 CDI 181
 IVIG 179
 Bacteriological confirmation 180
 Bacteriostasis 95
 Binding site pockets 10
 Bioaccumulation in sanitary devices 78
 Bioactive molecules 78, 101, 102, 127
 natural product 127
 Biocidal 81, 94, 96, 99
 activity 81, 94, 96, 99
 efficiency 96
 Biocidal compounds 92, 101
 broad-spectrum 92
 Biological evaluation 78, 111
 of medical devices 111
 Biomaterials 78, 79, 85, 87, 91, 92, 93, 107,
 108
 antibiotic-loaded 92
 anti-infective 92
 gentamicin-laden 79
 porous 91
 Biomedical devices 78, 80, 85, 87, 89
 permanent 87
 Blood 4, 49, 51, 109, 110, 112, 129, 152, 172,
 175, 176, 186, 188, 190, 193
 circulating 109, 110
 human 193
 peripheral 186, 190
 products, human 188
 retina barrier 129

- Boc-protected methyl ester 34
Bone marrow 133, 135, 186
 depression 135
 suppression 133
- C**
- Candida* 57, 59, 60, 61, 62, 63, 64, 79
 albicans 57, 59, 60, 63, 64, 79
 aspergillus 79
 glabrata 59, 60, 61
 glabrata 61, 62
 krusei 57
 parapsolisis 60
Candidiasis 79, 178
 chronic mucocutaneous 178
Carcinogenesis 67
Cardiac arrest 134
Catalytic 9, 11, 29, 35, 36, 52
 activity 52
 hydrogenation 29, 35, 36
Catheters 50, 78, 89, 92, 103, 109, 110
 central venous 92
 retrograde coronary perfusion 110
 sulfadiazine-coated 92
Cells 19, 50, 51, 52, 67, 79, 94, 102, 103, 129,
 137, 140, 141, 144, 145, 146, 166, 167,
 168, 169, 170, 172, 173, 174, 178, 186,
 187, 192
 antigen-presenting 174
 coenocytic 51
 eukaryotic 79, 94, 102, 103
 gondii-infected 137
 immune 173
 infected 140, 141, 145
 lysis 94
 malignant 168
 mammalian 144, 145
 microbial 103
 penetration 129
 permeability 19
 proliferation 67
 renal 146
 tumor 52
 tumour 168
 selectivity 94, 103
 separation systems 110
Cerebral toxoplasmosis 129, 132, 136
 chronic 132
Chemical vapor deposition (CVD) 81, 84
Chitinases 51, 52, 53, 56, 57, 66
Chitodextrins 52
Chitosan nanofibers 82
Chronic lymphocytic leukaemia 178
Cirrhosis 2, 3, 4, 5, 6, 7, 8
 advanced 5
 compensated 3, 4, 5, 6, 7, 8
 SVR rates 6
Clindamycin 131, 134, 136, 137, 138, 141,
 142, 144
 intravenous 136
Clostridium difficile 23, 38, 181
 infection (CDI) 23, 38, 181
Clostridium tetani 180, 181
Colletotrichum gloeosporioides 66
Compounds 27, 28, 31, 55, 56, 57, 64, 65, 67,
 68, 84, 87, 95, 99, 101, 102, 103, 139,
 140, 149, 150
 alkaloids 140
 anti-biofilm 103
 biocides 101
 inorganic 84, 87
 isolated 64, 67
 phenolic 139
 phosphate-containing 95
 target 31
Congenital 127, 129, 130, 131, 133, 134, 135,
 136, 178
 acquired immune deficiency syndrome 178
 anomalies 178
 infection 131, 135
 long QT syndrome 134
 toxoplasmosis 127, 129, 130, 131, 133,
 135, 136
 treatment of 133, 135
Copy number variations (CNV) 177
Core lipid nanocapsules 149, 151
Corticosteroids 137
 systemic 137
Corynebacterium diphtheriae 180
Covalent immobilization 84, 86, 88, 89, 100,
 101
 non-reversible 86
 of antimicrobials 101
 of biomolecules 89
Crude methanol extract 142
Curcuma longa 139, 145, 148
 ethanol extract 145
 extracts 145
 turmeric 148

Cysteine proteases 52, 64, 65, 66
 Cytokines 52, 140, 145, 187, 191
 blocking proinflammatory 191
 inflammatory 140, 145
 Cytokinesis 51
 Cytomegalovirus 185
 Cytoplasm 94, 105

D

Damage 94, 107, 128, 130, 132
 effective 94
 fatal 128
 inflammatory 132
 Death 79, 129, 133, 135, 181, 182, 188
 fetal 135
 rapid cell 129
 Dendritic cells 172, 173, 174, 191
 immature 172
 Dengue virus infection 191
 Deposition 81, 82, 83, 84, 91
 chemical vapor 81, 84
 physical vapor 81, 82
 pulsed laser 83
 Dermatomyositis 192
 Design of synthetic antimicrobial polymers 94
 Diabetes mellitus 189
 Diarrhea 53, 181
 antibiotic-associated 181
 Diphtheria-tetanus-pertussis (DTP) 180
 Direct-acting antivirals (DAAs) 1, 2, 4, 5, 6, 7,
 8, 9, 38
 Diseases 6, 7, 49, 54, 127, 129, 130, 132, 133,
 136, 146, 153, 165, 166, 168, 177, 178,
 180, 183, 184, 185, 187, 189, 191
 advanced-stage kidney 6
 auto-immune 168
 autoimmune heart 189
 autoimmune thyroid 189
 chronic granulomatous 178
 chronic kidney 6, 7
 congenital 129
 cytomegalovirus 185
 immune deficiency 136
 infection-induced 189
 inflammatory 146
 mycobacterial 178
 neglected tropical 49
 neurological 165
 preventing 165

 preventing relapsing 153
 renal 3
 viral 183, 184, 187
 Disorders 1, 38, 129, 177, 178, 187, 190, 192
 cell-mediated immunological 129
 extrahepatic 1
 genetic 177
 hematological 38
 immunological 187
 inflammatory 190
 neurological 192
 oncological 187
 DNA damage 129, 137
 in retinal cells 137
 DNase 102
 Domains 52, 67, 95, 166, 174, 19
 cytoplasmic 174
 cytoplasmic 174, 190
 extracellular 174
 non-catalytic 52
 transmembrane 174
 variable antigen binding 166
 Drug resistance 2, 38, 49, 135, 138
 infections 49
 Drugs 2, 8, 9, 11, 12, 14, 17, 37, 38, 56, 67,
 81, 86, 127, 128, 130, 131, 133, 134,
 135, 137, 138, 139, 149, 152, 153, 185
 antitoxoplasmic 137
 antiviral 37
 appropriate antibacterial 185
 generation 2
 ideal anti-Toxoplasma 131
 peptididomitic 14
 pharmacokinetic profile of 128, 149
 spectrum antimicrobial 56
 susceptibility 153
 synthesis approaches 17
 synthetic 127
 top-selling 67
 uncostly generic 38
 Drug therapies 127
 current 127
 effective 127

E

Ebola virus 183, 184, 187
 disease (EVD) 183, 184
 surface glycoprotein 187
 Effective antimicrobial measures 80

Effects 17, 95, 127, 131, 133, 134, 139, 140, 144, 146
 anti-toxoplasmic 133, 134, 144
 bactericidal 95
 cardiovascular 17
 chemotherapeutic 127, 139
 hepatoprotective 139
 immune-stimulatory 144
 immunomodulatory 140, 146
 lethal 131
 neuroprotective 140
 Encephalitis 127, 183
 virus-induced 183
 Endocarditis 79
 Endocytosis 172
 Endopeptidases 52
 Enzymes 12, 49, 50, 51, 52, 53, 87, 90, 94, 95, 101, 102, 131, 141
 biocidal 101
 iconic 52
 mutant 12
 proteolytic 102
 stable 52
 Epstein-Barr virus 65
Escherichia coli 53, 58, 59, 95
 Exposure 179, 183, 186, 189
 environmental 189
 sexual 186
 Extracts 50, 54, 113, 139, 141, 142, 143, 144, 145, 146, 147, 148
 betle 143
 crude 141, 142, 144
 effective 143, 145
 ethanol 142, 143, 144, 145, 147
 ethanolic 147, 148
 garlic 146
 medical device 113
 methanol 141, 145
 root 141

F

Fabrication 91
 Fab specificities 176
 Factors 67, 78, 82, 86, 98, 107, 128, 138, 170, 177, 178, 184
 environmental 107, 178
 fabrication 86
 numerous 184
 parasite 128

FAS ligand-receptor interaction 174
 Ferric reducing antioxidant potential (FRAP) 147
Ficus 51, 53, 56, 63, 64, 66
carica 51, 53, 56, 63, 66
elastica 56, 64
microcarpa 66
 Fighting 145, 171, 179, 182, 186, 187
 infectious diseases 179, 186
 microbial infection 187
 microbial threats 171
 toxoplasma parasite 145
 viral infections 182
 Food 49, 51, 107, 108, 127, 128, 185
 contaminated 127
 Furanocoumarin 57

G

Genes 167, 188, 189, 191
 immune activation 191
 numerous 189
 Genetic 3, 67
 patrimony 67
 resistance barrier 3
 Genotoxic damages 140
 Genotoxicity 109, 111
 Genotype 3, 4, 5, 6, 7, 8, 25, 38, 128, 129, 138
 prior costly 3
 Ginger root extract 140
 Ginkgolic acids 145, 146
 Glycoside hydrolase (GH) 52
 Gold nanospheres 149, 150, 151
 Grazoprevir synthesis 29, 30
 Growth 65, 78, 79, 80, 97, 103, 114, 142, 143, 151
 control pathogenic 79
 fungal 65
 inhibition 142, 143
 microorganism 114
 staphylococcal biofilm 103
 Guillain-Barré syndrome 182, 191

H

Haemolytic anaemia 176
 HeLa cell cultures 146
 Hematopoiesis 135
 Hemodialysis 38

Hepatic decompensation 2, 5
 Hepatitis infection 38
 Hepatocytes 139
 Herpes simplex 63
 HFF cells 143, 146
 infection 143
 viability 143
 Housekeeping function 171
 Human antibody responses 170
 Human foreskin fibroblasts (HFF) 142, 143, 145
 cells 143
 Human globulin 165, 173, 193
 Human hyperimmune globulin (HHG) 185, 186
 Human hyperimmune globulin product 185
 Human IgM 168, 173
 memory 168
 Human immune globulins 181, 186
 Human leucine-rich amelogenin peptide 89
 Hydrolases 51, 52
 glycosyl 52
 Hydrolysis 17, 32, 51, 52, 91
 amide 17
 Hyper IgM syndromes 178, 190
 Hyperimmune globulin (HG) 179, 182, 184, 185, 186, 192, 193
 in fighting bacterial infections 179
 in fighting viral infections 182
 Hyperimmune immunoglobulins 184, 192
 well-defined 192
 Hyperimmune IVIG prophylaxis 192
 Hyperimmunization 189
 tetanus toxoid 189

I

IgG 173, 174, 175
 aggregation 175
 complexes 175
 molecules 173, 174
 IgG antibodies 169, 179, 180
 natural 169
 protective antitoxin 179
 IgM 169, 176, 192
 complementary idiotypic 169
 mediated complement deposition 192
 paraproteinaemias 176
 Immune 144, 165, 173, 177, 189
 complexes 173

 deficiency 165
 dysregulation 177, 189
 evasion 144
 Immune globulin 181, 185, 186
 intravenous 185, 186
 Immune response 97, 137, 144, 146, 166, 167, 170, 173, 176, 190
 cellular 176
 induced 170
 Immune system 87, 128, 129, 151, 165, 168, 172, 177
 homeostasis 165
 human 177
 humoral 165
 Immunity 129, 130, 140, 175, 186, 190
 adaptive 168
 adaptive host 129
 antibody-mediated 175
 cellular 190
 normal 130
 protective 140
 Immunobulin preparations 175
 Immunocompetent patients 131, 137
 Immunocompromised patients 129, 130, 132, 136, 153
 Immunodeficiency 178, 179
 secondary 179
 Immunoglobulin(s) 172, 173, 175, 177, 183
 equine rabies 183
 fractions 175
 genes 177
 human rabies 183
 monomeric 173
 purified 175
 therapy 172, 173
 Infections
 life-threatening 78
 non-SARS-CoV 184
 parasitic 129
 rabies 186
 toxoplasmic 153
 wound 79
 Infectious diseases 8, 9, 49, 53, 55, 56, 67, 127, 128, 139, 140, 165, 174, 178, 179, 183, 187
 acquired 178
 acute 183
 emerging 49
 hyperimmune 193
 therapies 53, 165

treatment of 8, 56, 67, 165
 Inflammation 97, 137, 138, 151, 152, 165, 192
 chronic 97
 severe 137
 Inflammatory myopathies 192
 Influenza virus 169
 Inhalational anthrax 185
 Inhibition 14, 31, 33, 56, 103, 131, 143, 144,
 145, 172, 191
 enzyme 14
 Inhibitors 1, 3, 4, 6, 7, 11, 12, 14, 27, 31, 53,
 131, 134
 dihydrofolate reductase 134
 mitochondrial 131
 potent hexapeptide 14
 trypsin 53
 Inhibitory effect 142, 143, 144, 191
 direct 191
 displayed significant 142
 gondii growth 144
 Injection 145, 180
 intraperitoneal 145
 Injury 141, 185, 191
 complement-mediated tissue 191
 preventing antibody-mediated 191
 re-oxygenation 141
 Innate 93, 167
 immune defenses 93
 like lymphoid cells 167
 Invasion 102, 129, 131, 169, 172
 cellular 129
 host cell 131
 microbial 169, 172
 Ion Beam Assisted Deposition (IBAD) 83
 IVIG therapy 183, 190, 192
 adjunctive 183

J

Japanese encephalitis virus 183
Jatropha 63, 64
 curcas 63
 gossypifolia 64
 mollissima 64

K

Kawasaki disease 190, 191
 Ketoamide inhibitor 13, 14

macrocyclic 14
Klebsiella pneumoniae 59, 60, 61, 62

L

Latex extraction methods 56
 Latex metabolites 51
 Latices 49, 64
 elastica 64
 plant-derived 49
 Laticifers 50, 51
 articulated 51
 branch 51
 nonarticulated 51
 Leishmania 52, 66
 amazonensis 66
 Leishmaniasis 52
 Leucine-rich amelogenin peptide (LRAP) 89
 Leucovorin supplements 133
 Leukocyte removal filter 110
 Lipid(s) 94, 99, 103, 104, 105, 141
 bilayer 104
 layer 99
 monolayers 104
 peroxidation 141
 Lipopolysaccharides 94
 Liposomes 149, 151, 152
Listeria monocytogenes 63
 Liver 2, 28, 139, 147, 149, 150, 151, 152, 185
 ameliorate 139
 cancer 2
 Liver diseases 1, 2, 130, 139, 144, 186, 189
 autoimmune 189
 chronic 2, 130
 function 139
 imprints 144
 transplantation 1, 2, 186
 LRBA deficiency 178
 Lymphadenopathy 128
 Lysosomal compartment 174
 Lysozyme 85, 90, 101
 anchorage 90
 immobilized 85

M

Macrocyclic 14, 35
 ketoamide, bound 14
 Macrolide antibiotic 131

- broad-spectrum 131
 - Macromolecules 81, 84, 87, 94
 - cationic amphiphilic 94
 - cationic hydrophilic-hydrophobic 94
 - Macrophages 151, 172, 191
 - activating 151
 - infected 151
 - Malaria 49, 142
 - Malfunction 177
 - Malignancy 1, 177, 178, 189
 - Malnutrition, severe 178
 - Mass vaccination 180
 - Medications 33, 131, 134, 136, 137, 138, 139, 152, 179, 193
 - antitoxoplasmic 134
 - anti-toxoplasmic 138
 - artificial 139
 - atovaquone maintenance 131
 - immunosuppressive 138
 - Medicinal 50, 54, 127, 128, 130, 139, 140, 141, 142, 144, 146, 147, 148, 153
 - herbs 141, 144, 146
 - plants 50, 54, 127, 128, 130, 142, 147, 148, 153
 - extracts 139, 140
 - Medicine 53, 54, 127, 183
 - conceptualizes tradition 53
 - ethnoveterinary 54
 - MERS 187, 188
 - coronavirus 187
 - virus 188
 - Metabolism 101, 112, 131
 - folate 131
 - folic acid 131
 - reducing biofilm 101
 - Metalloproteases 52
 - Methanolic extracts 147, 148
 - Methicillin-resistant *S. aureus* (MRSA) 182
 - Microbes 51, 55, 165, 168, 171, 188, 193
 - killed 188
 - Microbial 52, 101, 103
 - infections 52
 - resistance 101, 103
 - Micrococcus* 57, 85
 - luteus* 57
 - lysodeikticus* 85
 - Microorganisms 79, 86, 93, 101, 102, 103, 107, 151, 171, 172, 173, 178, 179
 - inactivated 179
 - invading 172, 173
 - invading pathogen 103
 - Middle east respiratory syndrome (MERS) 49, 188
 - Molecular 186, 189, 191
 - epitope, single 186
 - mimicry 189, 191
 - template 127
 - Monoclonal antibodies 165, 186, 187, 190, 192, 193
 - generating human 186
 - humanized 186
 - important therapeutic 190
 - murine 186
 - producing 187
 - producing human 186
 - Morbidity 4, 130, 136, 192
 - diminished liver-related 4
 - reducing 192
 - MTT assay 146
 - Multifocal 182, 190, 191
 - motor neuropathy (MMN) 190, 191
 - neuropathy 182
 - Multiple 189, 191
 - effects of IVIG 191
 - sclerosis 189
- N**
- Nanoparticles 81, 82, 95, 96, 106, 107, 128, 149, 151, 152, 153
 - combination of 128, 153
 - copper oxide 82
 - core-shell latex 149, 151
 - functionalized magnetite 96
 - green 153
 - inorganic 107
 - metallic 82
 - metallic oxide 82
 - spiramycin-loaded chitosan 149
 - Nanotechnology 106, 114, 127, 128, 149, 153
 - application of 149, 153
 - conjugates 153
 - use of 106, 127
 - Necrosis 129, 137, 139, 145, 191
 - leading 129
 - tumor 145
 - tumour 191
 - Neuromuscular junction 181, 183
 - Neutralization assay 184
 - Non-fouling surface 97

- biocompatible 97
 - Nucleophilic aromatic substitution 26, 36
- O**
- Ocular toxoplasmosis 136, 137
 - Oil of *Curcuma longa* 145
 - Onychomycosis 79
 - Oxide 84, 90, 145, 151
 - graphene 90
 - nitric 145, 151
 - Oxidizing atmosphere 85
- P**
- Pangenotypic drugs 38
 - Papain 51, 52, 57, 65, 179
 - digestion 179
 - like cysteine proteases, (PLCPs) 51, 52, 57
 - Papaver somniferum* 51, 54
 - Parasites 55, 65, 127, 128, 131, 137, 139, 146, 151, 152
 - death 65
 - load 151
 - intracellular 127, 128
 - multiplication 146
 - replication 131
 - survival 131
 - Pathogen 81, 172
 - aggregation 172
 - growth 81
 - Pathogens 8, 51, 53, 56, 78, 79, 80, 93, 114, 166, 167, 168, 171, 172, 176, 178, 179, 182, 192
 - cells internalise microbial 172
 - drug-resistant 8
 - endemic 176
 - infectious 53
 - opportunistic 78, 114
 - pre-existing 93
 - Pathologies 129, 171, 188, 189, 190, 192
 - autoimmune 189
 - Pathways 8, 9, 66, 107, 167, 173
 - alternative complement 173
 - classical 173
 - novel molecular 8
 - signal transduction 167
 - Penetrate ocular 130, 131
 - tissues 131
 - Penicillium chrysogenum* 62
 - Peptide bond 19, 32, 51, 52
 - coupling 19
 - hydrolyzes 52
 - Peripheral 136, 137, 190
 - blood cell 136
 - lesion 137
 - tolerance mechanisms 190
 - Peritoneal 142, 143, 144, 146, 152, 167
 - cavity 167
 - fluid 142, 143, 144, 146, 152
 - Peroxidase 66
 - Phagocytosis 168, 172, 174, 180
 - Pharmacodynamic actions 147
 - Phospholipids 94, 95
 - acidic 95
 - neutral zwitterionic 94
 - Physical vapor deposition (PVD) 81, 82
 - Planktonic bacteria cells 97
 - Plant 52, 55, 64, 153
 - bioactive compounds 55
 - chitinases 52
 - cysteine proteases 52
 - lectins 52
 - metabolites 153
 - nematodes 64
 - Plasma 83, 85, 86, 91, 141, 166, 175, 179, 180, 181, 183, 184
 - convalescent 184
 - convalescent patient 184
 - coalescent 184
 - fractionation project, large 175
 - immune 184
 - oxygen 86, 91
 - radiation 85
 - Plumeria rubra* 66
 - Pneumonitis 127
 - Polyclonal immunoglobulin products 165
 - Polymeric 89, 95, 96, 112, 149, 151, 152
 - biocides 96
 - matrices 89
 - Polymeric nanocapsules 149, 151, 152
 - polylactide 149
 - Polymers 88, 89, 91, 93, 95, 96, 97, 98, 99, 100, 101, 107, 149, 151
 - alkylated 99
 - bioactive 99
 - biocidal 98
 - biological 89
 - cationic 96, 98

lysine-like 100
 natural 149
 polycationic 96
 polynorbornene derivatives 99
 synthetic pluronic 101
 Polymorphisms 35, 174, 189
 single nucleotide 174
 Polymorphonuclear leukocytes 172
 Polymyositis 189, 192
 Polyphyletic origins 50, 67
 Polyprotein 3
 Polysaccharides 50, 182
 water-soluble 50
 Primary Immunodeficiency (PIDs) 165, 177, 178
 Process 8, 51, 53, 78, 81, 82, 84, 86, 90, 91, 96, 101, 102, 108, 110, 111, 170, 172, 174, 187, 189, 192
 adaptive 53
 chemical 84
 coagulation 51
 establishment 101
 evaporation 83
 exact 169
 expensive 175
 grafting-from 96
 healing 78
 layer-by-layer 90
 of phagocytosis 172, 174
 physiological 101
 regulatory 8
 risk management 111
 wound healing 102
 Progressive 183, 186
 paralysis 183
 vaccinia 186
 Proline skeleton 35
 Properties 56, 57, 64, 65, 78, 79, 88, 89, 92, 93, 94, 101, 106, 140, 176
 adequate mechanical 89
 anti-adhesive 101
 anti-infective 56, 57, 64, 65, 92
 anti-microbial 79
 antiprotozoal 140
 biocidal 101
 functional binding 176
 intrinsic 93
 low cytotoxicity 106
 selective permeability 94

Prophylaxis 127, 139, 153, 165, 175, 179, 185, 186, 189, 192
 antimicrobial immunoglobulin 189
 postexposure 186
 transient post-exposure 186
 Protease 12, 14, 106
 crystal structures 12
 degradation 106
 inhibitor complexes 14
 Protease inhibitor(s) 2, 3, 4, 5, 13, 53
 cysteine 53
 first-generation HCV 2
 grazoprevir 5
 macrocyclic 13
 pangenotypic 3
 paritaprevir 4
 Protease(s) 1, 3, 5, 6, 9, 12, 13, 27, 28, 51, 52, 53, 55, 56, 64, 65, 105
 aspartic 52, 53
 secreted 105
 serine 52, 53, 65
 third generation 6
 structure 9
 Proteins 1, 2, 3, 51, 52, 53, 65, 66, 68, 87, 94, 96, 101, 102, 104, 129, 140, 141, 143, 179
 apoptotic 140
 bi-functional 9
 chitin-binding 53, 65
 contaminating 179
 discharging 129
 essential functional 94
 extracellular matrix 102
 green fluorescent 143
 hemagglutinin 141
 low-molecular-mass 179
 nonstructural 1
 target HCV 2
 viral 2
 Proteolytic 3, 105
 degradation 3
 inactivation 105
 Pseudomembranous colitis 181
Pseudomonas aeruginosa 60, 65, 79
Psidium guajava 142, 147
Psuedomonas aeruginosa 61
 Psychoactive Drugs 53
 Public-health disasters 176
 Pulsed laser deposition (PLD) 83

R

Reactants 21, 23, 80, 88
 carboxyl acid 23
Reaction 17, 18, 19, 20, 21, 23, 24, 25, 28, 29,
 32, 34, 35, 36, 83, 87, 89, 137, 180, 186
 allergic 180
 amine group 34
 chemical 83
 ether bond formation 34
 hypersensitivity 137
 imine 25
 imine formation 23
 intramolecular amine 17
 ketone halogenation 17
 nucleophile 34
 redox 87
 severe systemic 186
Reactivating attacks 137
Reactive 107, 189
 arthritis 189
 oxygen 107
Receptors 149, 166, 167, 171, 172, 173, 174,
 181, 183, 190
 acetylcholine 183
 activating 174
 activatory 190
 apoptotic body 172
 cell 166, 167
 cell antigen 190
 high-affinity 173
 human phagocytic 172
 immunoglobulin 171
Regulation 67, 101, 102, 105, 171, 189, 190,
 192
 effector function 171
 gene 105
 metabolic 102
Relapse 132, 135, 138
Renal dysfunction 175
Replication 1, 3, 9, 141, 145, 152, 166
 cellular 3
 promoted HIV-1 66
 viral 1, 3, 9
Respiratory syncytial virus (RSV) 65, 192
Retinal 137
 cells 137
 lesion size 137
Retinochoroiditis 136, 137, 138
 active 137

 toxoplasmic 136, 138
Rheumatoid arthritis 130, 191
Risk assessment of nanomaterials 113

S

Salivary glands 183
Salmonella typhimurium 64
Secretions 140, 166, 169
 inflammatory cytokine 140
Sequential organ failure assessment (SOFA)
 188
Severe combined immuno defficiencies 178
Silver 83, 92, 107
 deposition 83
Silver nanoparticles 82, 86, 92, 149, 153
 metallic 92
Sjogren's syndrome 189
Sodium dodecyl sulfate (SDS) 152
Sophora flavescens extracts 145
Spiramycin 131, 132, 133, 134, 135, 142, 143
Splenectomy 186
Staphylococcus epidermidis 58
Staphylococcus saprophyticus 63
Streptococcus pneumoniae 58, 61, 62, 182
Structure 10, 11, 14, 15, 27, 35, 52, 67, 87, 94,
 96, 103, 167, 173, 186
 bilayer phospholipid 96
 biomimetic 87
 chemical 67
 crystal 10, 11, 27
 endogenous 167
 hexameric 173
 macrocyclic 35
 scaffold 15
 secondary 103
 threedimensional 186
Structure 20, 23, 28, 31, 33, 36
 activity relationships (SAR) 20
 of asunaprevir 17
 of deldeprevir 23
 of grazoprevir 28
 of narlaprevir 31
 of vedroprevir 33
 of voxilaprevir 36
Sustained virological response (SVR) 2, 4, 6,
 7, 8
Synthesis 18, 19, 17, 20, 22, 23, 25, 29, 30,
 31, 34, 35, 36, 37, 65, 85, 88, 89, 93,
 104, 131, 139, 153

chitin 65
 gondii folic acid 131
 green 153
 nucleic acid 104
 of alcohol precursor 36
 of asunaprevir vinyl cyclopropyl subunit 19
 of carboxylic acid 29
 of chloroisoquinolinoxy proline 18
 of danoprevir 22
 of deldeprevir 23, 25
 of narlaprevir 31
 of voxilaprevir 37
 purines 131
 vaccine 139
 Synthetic 32, 88, 94
 antimicrobial polymers 94
 peptides 88
 route for narlaprevir 32
 Systemic 92, 112, 173, 189, 191
 cellular involvement 189
 lupus erythematosus (SLE) 173, 189, 191
 toxicity 92, 112

T

Tachyzoites 128, 129, 133, 134, 137, 141,
 142, 143, 144, 145, 146, 150, 151
 growth 142
 reproduction 144
 surface 150
 Targets 8, 38, 104, 107, 186
 bacterial 107
 global 38
 intracellular 104
 molecular 186
 viral 8
 Tautomerization 24
 Tetanus 180, 181, 185, 187, 189
 antitoxin 181
 equine 181
 toxoid 181
 vaccine 181
 TFA trifluoroethanoic acid 39
 Thalassemia 38
 Therapeutic 110, 138, 143
 activity of artemisia annua 143
 apheresis equipment 110
 courses ranging, long 138
 Therapeutic effects 145, 146, 151, 166
 multiple 145
 Therapy 1, 2, 3, 5, 7, 8, 66, 129, 136, 137,
 138, 153, 165, 166, 175, 176, 178, 181,
 182, 190
 active antiretroviral 66
 anti-HIV 1
 antitoxoplasmic 153
 contemporary 3
 curative 182
 current antiretroviral 66
 developing new anti-HCV 3
 multidrug 137
 off-label 190
 oral antiviral DAA combination 2
 postnatal 136
 reactivation 66
 regarding DAA combination 1
 Thrombosis 109, 110, 111
Thymus vulgaris 139, 147
Thymus vulgaris ethanol extract 139, 140
Tinospora crispa stem extract 142
 Tissues 50, 55, 79, 93, 102, 109, 111, 127,
 128, 129, 130, 135, 137, 146, 151, 152
 cerebral 130
 connective 79
 laticiferous 55
 ocular 137
 placental 127
 Titanium 84, 90
 implants 90
 tetra-isopropoxide 84
 TLR ligands 189
 Toll-like receptors (TLRs) 172
 Tonsillectomy 186
 Toxicity 51, 99, 109, 111, 127, 131, 133, 135,
 141, 151
 developmental 109, 111
 fetal 127, 131
 hematologic 135
 renal 133
 reproductive 111
 selective 141
 Toxic megacolon 181
 Toxins 53, 179, 180, 181, 182, 187
 bacterial 179, 180
 cholera 53
 circulating 180
 deadly 187
 unbound 181
 Toxoplasma 140, 152
 cyst 140

reactivation 152
 Toxoplasma tachyzoites 139, 141, 142, 143, 144, 145, 146, 147, 151, 152
 and tissue cysts 139
 in comparison 143, 147
 intraperitoneal inoculation of 143, 146
 treatment of 151, 152
 Toxoplasma tissue cysts 127, 128, 134, 137
 formation 134
Toxoplasma gondii 53, 127, 128, 129, 153
 Toxoplasma infection 128, 139, 143, 145, 147, 149, 152, 153
 defeating 128
 in murine models 145
 medicinal plants used to treat 139, 147
 treatment 149, 153
 Toxoplasma parasite 127, 131, 132, 133, 135, 136, 138, 141, 142, 143, 146, 151, 152
 and formation of tissue cysts 138
 killing 151
 Toxoplasmic encephalitis 131, 132, 133, 135, 136, 152
 development of 152
 Toxoplasmosis 127, 128, 129, 130, 131, 132, 133, 135, 138, 139, 140, 147, 149, 152
 active 132
 chronic 132, 149, 152
 fetal 133
 human 129, 138, 139
 reactivated latent 152
 Transmission 49, 127, 128, 131, 135, 181
 congenital 131
 placental 127, 135
 sexual 49
 vertical 131, 133
 Transplantation, organ 127, 128
 Treatment 38, 87, 91, 130, 136, 137, 138, 141, 143, 148, 149, 179, 180, 182, 193
 atypical presentations warrant 137
 cancer 143
 cost-effective 193
 effective 38, 180
 formalin 179
 gondii infection 148, 149
 heat 87
 initial 138
 physicochemical 91
 postnatal 136
 prenatal 135
 symptom 182

target 130
 therapeutic 141
 Treatment failures of toxoplasmosis 138
 Triclosan 103, 152
 Tripeptidic carboxylic acids 15
 Tyrosine-based activation motif 174

U

Usnic acid 151
 liposomal 151

V

Vaccination 180, 182
 booster 180
 Vaccines 130, 183
 antirabies 183
 safe 130
 Vaccine-type pneumococci 182
 Vancomycin 86, 93, 181
 Vapor trapping CVD method 84
 Vero cells 141, 153
 infected 141
 Vinyl cyclopropyl amino acid 20
 Viral infections 1, 165, 182, 183, 184, 185, 188, 193
 acute 193
 chronic 1
 common 182
 Virions, inactivated 183
 Virus 1, 3, 8, 53, 66, 182, 183, 185, 192
 positive-stranded RNA 3
 rabies 183
 respiratory syncytial 192

W

West Nile virus (WNV) 182
 Wiskott-Aldrich syndrome 178
 World health organization (WHO) 2, 49, 53, 55, 180
 Worm infections 50

Z

Zika virus infection 182
Zingiber officinale 140, 147
 extract 140



PROF. DR. ATTA-UR-RAHMAN, FRS

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.